SCHEMBL16239010

SCHEMBL16239010

Cc1cccc2c1NC(=O)CC(=O)N2c1ccc(NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 6/20 0.49
BRD4 O60885 2/20 0.43
CREBBP Q92793 2/20 0.43
MAPT P10636 3/20 0.41
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA9 Q16790 1/20 0.37
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
MEN1 O00255 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
RORC P51449 2/20 0.35
DRD2 P14416 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
LIPE Q05469 1/20 0.35
NR1I3 Q14994 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16239668 0.88 P2RX4 (0.48) P2RX4BRD4CREBBPMAPTMEN1
SCHEMBL16239312 0.83 P2RX4 (0.72) P2RX4
SCHEMBL14972514 0.83 P2RX4 (0.47) P2RX4BRD4CREBBPDRD2PTGDR2
SCHEMBL16239178 0.81 P2RX4 (0.50) P2RX4MAPTRAB9A
SCHEMBL16239200 0.77 MAPT (0.46) P2RX4BRD4CREBBPMAPTMEN1
SCHEMBL14972870 0.76 P2RX4 (0.44) P2RX4BRD4CREBBPMAPTDDB1
SCHEMBL16239054 0.76 MAPT (0.52) P2RX4MAPTMEN1RAB9AKMT2A
SCHEMBL28426652 0.73 BRD4 (0.40) BRD4CREBBPMAPTCA12CA1
SCHEMBL16239282 0.72 P2RX4 (0.72) P2RX4
SCHEMBL30297452 0.72 P2RX4 (0.72) P2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2024-12-19 US disclosed
US-12116351-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2024-10-15 US disclosed
US-20220380322-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2022-12-01 US disclosed
US-11434207-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2022-09-06 US disclosed
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2020-07-16 US disclosed
US-10633349-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2020-04-28 US disclosed
US-20180201587-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2018-07-19 US disclosed
US-9969700-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD. (JP) 2018-05-15 US disclosed
EP-2803662-B1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO (JP) 2017-03-01 EP disclosed
US-20160280667-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2016-09-29 US disclosed
US-9382236-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2016-07-05 US disclosed
US-20140357858-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2014-12-04 US disclosed
EP-2803662-A1 P2X4 RECEPTOR ANTAGONIST Nippon Chemiphar Co., Ltd. (JP) 2014-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380322-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 P2RX4 6/4885BRD4 418/4885CREBBP 1422/4885
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 P2RX4 5/4885BRD4 416/4885CREBBP 1459/4885
US-12116351-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 P2RX4 6/4885BRD4 418/4885CREBBP 1422/4885
US-20160280667-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 P2RX4 6/4885BRD4 421/4885CREBBP 1412/4885
US-20140357858-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 P2RX4 6/4885BRD4 418/4885CREBBP 1422/4885
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 P2RX4 6/4885BRD4 418/4885CREBBP 1422/4885
US-11434207-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 P2RX4 6/4885BRD4 418/4885CREBBP 1422/4885
US-10633349-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 P2RX4 6/4885BRD4 418/4885CREBBP 1422/4885
US-20180201587-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 P2RX4 6/4885BRD4 418/4885CREBBP 1422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.